ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ДИСТАНЦИОННОЙ ЛУЧЕВОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С РАЗЛИЧНЫМ РИСКОМ ПРОГРЕССИРОВАНИЯ
https://doi.org/10.21886/2308-6424-2015-0-3-42-53
Аннотация
Об авторах
П. Д. ДемешкоБеларусь
С. А. Красный
Беларусь
Список литературы
1. Океанов, А.Е. Статистика онкологических заболеваний в Республике Беларусь (2003-2012) / А.Е. Океанов, П.И. Моисеев, Л.Ф. Левин ; Под редакцией О.Г. Суконко. – Минск : РНПЦ ОМР им. Н.Н. Александрова, 2013. – 373 с.
2. Biochemical outcome after radical prostatec- tomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. / A.V.D’Amico R.Whittington, S.B. Malkowicz et al. // JAMA – 1998. – Vol. 280. – P. 969-974.
3. Prostate cancer, version 2.2014 / J.L. Mohler, P.W. Kantoff, A.J. Armstrong et al. // J. Natl. Compr. Canc. Netw. – 2014. – Vol. 12 (5). – P. 686-718.
4. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer / G.D. Grossfeld, D.M. Latini, D.P. Lubeck et al. // J Urol. – 2003. – Vol. 169. – P.157–163.
5. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy / O. Yossepowitch, S.E. Eggener, A.M. Serio et al. // Eur. Urol. – 2008. – Vol. 53. – P. 950–959.
6. Cooperberg, M.R. Time trends and local variation in primary treatment of localized prostate cancer / M.R. Cooperberg, J.M. Broering, P.R. Carroll // J Clin. Oncol. – 2010. – Vol. 28. – P.1117–1123.
7. Multimodal treatment for high-risk prostate cancer with high-dose intensitymodulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial / A. Guttilla, R. Bortolus, G. Giannarini et al. // Radiation Oncology – 2014. – Vol. 9. – P. 24-34.
8. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group / P. Grimm, I. Billiet, D. Bostwick et al. // BJU Int. – 2012. – Vol. 109 (Suppl. 1). – P. 22-29.
9. Natural history of progression after PSA elevation following radical prostatectomy / C.R. Pound, A.W. Partin, M.A. Eisenberger et al. // J.A.M.A. – 1999. – Vol. 281 (17). – P. 1591–1597.
10. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes / P. Sooriakumaran, T. Nyberg, O. Akre et al. // B.M.J. – 2014. – Vol. 26. – P. 348.
11. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective / Y. Yoshioka, O. Suzuki, Y. Otani et al.// J. Contemp. Brachytherapy. – 2014. – Vol. 6. – P. 91-98.
12. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival / W.D. Heemsbergena, A. Al-Mamganib, A. Slotc et al. // Lebesque Radiotherapy and Oncology. – 2014. – Vol. 110. – P. 104–109.
13. Escalated dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial / D.P. Dearnaley, G. Jovic, I. Syndikus et al. // Lancet Oncol. – 2014. – Vol. 15. – P. 464–473.
14. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes / M.J. Zelefsky, Y. Yamada, Z. Fuks et al. // Int. J. Radiat. Oncol. Biol. Phys. – 2008. – Vol. 71. – P. 1028-1033.
Рецензия
Для цитирования:
Демешко П.Д., Красный С.А. ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ДИСТАНЦИОННОЙ ЛУЧЕВОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С РАЗЛИЧНЫМ РИСКОМ ПРОГРЕССИРОВАНИЯ. Вестник урологии. 2015;(3):42-53. https://doi.org/10.21886/2308-6424-2015-0-3-42-53
For citation:
Demeshko P.D., Krasny S.A. LONG-TERM RESULTS OF EXTERNAL BEAM RADIATION THERAPY IN MEN WITH NEWLY DIAGNOSED PROSTATE CANCER WITH DIFFERENT RISK OF PROGRESSION. Urology Herald. 2015;(3):42-53. (In Russ.) https://doi.org/10.21886/2308-6424-2015-0-3-42-53